Cargando…
Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter‐related infection treated with amikacin
The pharmacokinetics of amikacin makes it difficult to predict the appropriate dosing to avoid harmful side effects in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The implementation of therapeutic drug monitoring may be useful in controlling amikacin serum concentrations in...
Autores principales: | Kojya, Sanae, Shiohira, Hideo, Sunagawa, Yoshitsugu, Tsuneyoshi, Shoji, Kohagura, Kentaro, Ohya, Yusuke, Yonaha, Fusako, Hokama, Nobuo, Nakamura, Katsunori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303865/ https://www.ncbi.nlm.nih.gov/pubmed/32577250 http://dx.doi.org/10.1002/ccr3.2774 |
Ejemplares similares
-
Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis
por: Kochi, Masako, et al.
Publicado: (2016) -
Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
por: Falbo dos Reis, Pâmela, et al.
Publicado: (2021) -
Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
por: Aznar, Maria Luisa, et al.
Publicado: (2019) -
Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
por: Jin, Xuanyou, et al.
Publicado: (2020) -
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)